Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04306900 · ClinicalTrials.gov registry record · Phase 1
TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
A Phase 1 study, sponsored by Trishula Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 185
- Enrollment target
NCT04306900 is a Phase 1 study that has completed, run by Trishula Therapeutics. The registered enrollment target is 185 participants.
The verdict
NCT04306900, a Phase 1 study, has completed, sponsored by Trishula Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 185 participants
- Enrollment target
Study Summary
This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and promote anti-tumor immune response. This trial will study the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TTX-030 in combination with immunotherapy and/or standard chemotherapies.
Interventions
- COMBINATION_PRODUCT TTX-030, budigalimab, nab-paclitaxel and gemcitabine
- COMBINATION_PRODUCT TTX-030, budigalimab and mFOLFOX6
- COMBINATION_PRODUCT TTX-030, budigalimab and docetaxel
- COMBINATION_PRODUCT TTX-030 and mFOLFOX6
- COMBINATION_PRODUCT TTX-030 and budigalimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2020-03-30 |
| Est. Completion | 2024-03-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04306900
The ClinicalTrials.gov registry entry for NCT04306900 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 185 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Trishula Therapeutics, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which TTX-030, budigalimab, nab-paclitaxel and gemcitabine is the first listed.
NCT04306900 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04306900 about?
NCT04306900 is a clinical study titled "TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers". This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and promote anti-tumor i...
What is the current status of trial NCT04306900?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 185 participants. The study started on 2020-03-30. Estimated completion is 2024-03-27.
What interventions are being tested in trial NCT04306900?
The interventions under investigation include: TTX-030, budigalimab, nab-paclitaxel and gemcitabine (COMBINATION_PRODUCT), TTX-030, budigalimab and mFOLFOX6 (COMBINATION_PRODUCT), TTX-030, budigalimab and docetaxel (COMBINATION_PRODUCT), TTX-030 and mFOLFOX6 (COMBINATION_PRODUCT), TTX-030 and budigalimab (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04306900?
This trial is sponsored by Trishula Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.